RonaldGStollerMD

PubMed

• Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or l...
  Kimmen Quan, Philip A. Sutera, Karen M. Xu, Mark E. Bernard, Steven A. Burton, Rodney E. Wegner, Herbert J. Zeh, Nathan Bahary, Ronald G. Stoller, Dwight E. Heron> ;Practical radiation oncology. 2017 Oct 7
• 31 citations
  Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gas...
  Shah, M. A., Janjigian, Y. Y., Stoller, R. G., Shibata, S., Kemeny, M., Krishnamurthi, S. S., Su, Y. B., Ocean, A. J., Capanu, M., Mehrotra, B., Ritch, P. S., Henderso...> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 7
• 8 citations
  A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
  Rodon, J., Tawbi, H. A., Thomas, A. L., Stoller, R. G., Turtschi, C. P., Baselga, J., Sarantopoulos, J., Mahalingam, D., Shou, Y., Moles, M. A., Yang, L., Granvil, C.,...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Feb 14
• Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.
  Tawbi, H.,Christner, S. M.,Lin, Y.,Johnson, M.,Mowrey, E. T.,Cherrin, C.,Chu, E.,Lee, J. J.,Puhalla, S.,Stoller, R.,Appleman, L. R.,Miller, B. M.,Beumer, J. H.> ;Cancer Chemother. Pharmacol.. 2013 Oct 31
• Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.
  Tawbi, H. A.,Tran, A. L.,Christner, S. M.,Lin, Y.,Johnson, M.,Mowrey, E.,Appleman, L. R.,Stoller, R.,Miller, B. M.,Egorin, M. J.,Beumer, J. H.> ;Cancer Chemother. Pharmacol.. 2013 Sep 14
• 65 citations
  Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
  Boone, B. A., Steve, J., Krasinskas, A. M., Zureikat, A. H., Lembersky, B. C., Gibson, M. K., Stoller, R. G., Zeh, H. J., Bahary, N.> ;Journal of surgical oncology. 2013 Aug 21
• Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.
  Huali Wu, Ramesh K. Ramanathan, Beth A. Zamboni, Sandra Strychor, Suresh S. Ramalingam, Robert P. Edwards, David M. Friedland, Ronald G. Stoller, Chandra P. Belani, La...> ;International Journal of Nanomedicine. 2012 Oct 19
• A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a ...
  Chao, J., Synold, T.W., Morgan, R.J., Kunos, C., Longmate, J., Lenz, H., Lim, D., Shibata, S., Chung, V., Stoller, R.G., Belani, C.P., Gandara, D.R., McNamara, M., Git...> ;Cancer Chemother Pharmacol. 2012 Mar
• Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
  Argiris, A., Feinstein, T.M., Wang, L., Yang, T., Agrawal, S., Appleman, L.J., Stoller, R.G., Grandis, J.R., Egloff, A.M.> ;Invest New Drugs. 2012 Aug
• 2 citations
  Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
  Carneiro, B. A., Ramanathan, R. K., Fakih, M. G., Krishnamurthi, S. S., Lembersky, B. C., Stoller, R. G., Lancaster, S. L., Pinkerton, R. A., Crandall, T. L., Schmotze...> ;Clinical colorectal cancer. 2011 Aug 5
• Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies.
  Wu, H., Ramanathan, R.K., Zamboni, B.A., Strychor, S., Ramalingam, S., Edwards, R.P., Friedland, D.M., Stoller, R.G., Belani, C.P., Maruca, L.J., Bang, Y., Zamboni, W.C.> ;J Clin Pharmacol. 2011 Jan 13
• Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
  > ;J Liposome Res. 2011 Jun
• Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
  Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, Wu H, Friedland DM, Edwards RP, Stoller RG, Belani CP, Ramanathan RK> ;Clin. Pharmacol. Ther.. 2009-11-01
• Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors.
  Wu H, Ramanathan RK, Srychor S, Zamboni BA, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Zamboni WC> ;J. Clin. Oncol.. 2009-05-20
• Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies.
  Feinstein TM, Agrawal S, Stoller RG, Egorin MJ, Argiris A> ;J. Clin. Oncol.. 2009-05-20
• Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
  Zamboni, W.C., Ramalingam, S., Friedland, D.M., Edwards, R.P., Stoller, R.G., Strychor, S., Maruca, L., Zamboni, B.A., Belani, C.P., Ramanathan, R.K.> ;Clin Cancer Res. 2009-02-15
• A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
  Ramalingam, S.S., Egorin, M.J., Ramanathan, R.K., Remick, S.C., Sikorski, R.P., Lagattuta, T.F., Chatta, G.S., Friedland, D.M., Stoller, R.G., Potter, D.M., Ivy, S.P.,...> ;Clin Cancer Res. 2008 Jun 1
• Phase I trial of cetuximab (C) and dasatinib (D) in patients (pts) with advanced solid malignancies.
  Esteve FR, Stoller RG, Josephson A, Grandis JR, Egorin MJ, Argiris AE> ;J. Clin. Oncol.. 2008-05-20
• Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC).
  Owonikoko TK, Stoller RG, Petro D, Flaugh R, Hershberger PA, Belani CP, Argiris AE> ;J. Clin. Oncol.. 2008-05-20
• Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
  Ramalingam, S.S., Parise, R.A., Ramanathan, R.K., Ramananthan, R.K., Lagattuta, T.F., Musguire, L.A., Stoller, R.G., Potter, D.M., Argiris, A.E., Zwiebel, J.A., Egorin...> ;Clin Cancer Res. 2007 Jun 15
• Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
  Ramanathan, R.K., Egorin, M.J., Eiseman, J.L., Ramalingam, S., Friedland, D., Agarwala, S.S., Ivy, S.P., Potter, D.M., Chatta, G., Zuhowski, E.G., Stoller, R.G., Naret...> ;Clin Cancer Res. 2007 Mar 15
• 1 citation
  Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.
  Bratislav Janjic, Pedro Andrade, Xiaofei Wang, Julien Fourcade, Christine Almunia, Pavol Kudela, Adam Brufsky, Samuel A. Jacobs, David M. Friedland, Ronald G. Stoller,...> ;Journal of Immunology. 2006 Aug 15
• Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignanc...
  Ramalingam S, Parise RA, Egorin MJ, Argiris A, Stoller R, Beattie L, Aparicio A, Newman EM, Zwiebel J, Belani CP> ;J. Clin. Oncol.. 2006-06-20
• Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors.
  Zamboni WC, Friedland DM, Ramalingam S, Edwards RP, Stoller RG, Belani CP, Strychor S, Ou YC, Tonda ME, Ramanathan RK> ;J. Clin. Oncol.. 2006-06-20
• Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.
  Hitendra Patel, Ronald G. Stoller, Miklos L. Auber, Douglas M. Potter, Chao Cai, William C. Zamboni, Gauri J. Kiefer, Khalid Matin, Amy Schmotzer, Ramesh K. Ramanathan> ;Investigational New Drugs. 2006 Mar 8
• Join now to see all